{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:12:32Z","timestamp":1779898352901,"version":"3.53.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000096","name":"National Center on Minority Health and Health Disparities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Safety evaluation is an essential component of clinical trials. To protect study participants, these studies often implement safety stopping rules that will halt the trial if an excessive number of toxicity events occur. Existing safety monitoring methods usually treat these events as binary outcomes. A strategy that instead handles these as time-to-event (TITE) endpoints can offer higher power and a reduced time to signal of excess risk, but must manage additional complexities including censoring and competing risks. We propose the TITE-safety approach for safety monitoring, which incorporates TITE information while handling repeated analyses, censored observations, and competing risks appropriately. This strategy is applied to develop stopping rules using score tests, Bayesian beta-extended binomial models, and sequential probability ratio tests. Operating characteristics of these methods are studied via simulation for common phase 2 and 3 trial scenarios. Across simulation settings, the proposed techniques offer reductions in expected toxicities of 20% or more compared to binary data methods and maintain the type I error rate near the nominal level for various event time distributions. These methods are demonstrated through a redesign of the safety monitoring scheme for Blood and Marrow Transplant Clinical Trials Network 0601, a single arm, phase 2 trial that evaluated bone marrow transplant as treatment for sickle cell disease. Our R package \u201cstoppingrule\u201d offers functions to construct and evaluate these stopping rules, providing valuable tools for trial design to investigators.<\/jats:p>","DOI":"10.1093\/biomtc\/ujag097","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:42:43Z","timestamp":1778240563000},"source":"Crossref","is-referenced-by-count":0,"title":["TITE-safety: a robust time-to-event safety monitoring approach for clinical trials"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-681X","authenticated-orcid":false,"given":"Michael J","family":"Martens","sequence":"first","affiliation":[{"name":"Division of Biostatistics, Medical College of Wisconsin, Milwaukee , WI 53226 ,","place":["United States"]},{"name":"Center for International Blood and Marrow Transplant Research , Milwaukee, WI 53226 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Lian","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Lawrenceville, NJ 08648 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-4044","authenticated-orcid":false,"given":"Brent R","family":"Logan","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Medical College of Wisconsin, Milwaukee , WI 53226 ,","place":["United States"]},{"name":"Center for International Blood and Marrow Transplant Research , Milwaukee, WI 53226 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2026052711492618400_bib1","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/1097-0258(20001115)19:21<2899::AID-SIM597>3.0.CO;2-O","article-title":"Formal approaches to safety monitoring of clinical trials in life-threatening conditions","volume":"19","author":"Bolland","year":"2000","journal-title":"Statistics in Medicine"},{"key":"2026052711492618400_bib2","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/sim.2429","article-title":"A Bayesian stopping rule for a single arm study: With a case study of stem cell transplantation","volume":"25","author":"Chen","year":"2006","journal-title":"Statistics in Medicine"},{"key":"2026052711492618400_bib3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics."},{"key":"2026052711492618400_bib4","doi-asserted-by":"crossref","DOI":"10.1201\/9780203912881.ch2","volume-title":"Design of Early Trials in Stem Cell Transplantation: A Hybrid Frequentist-Bayesian Approach","author":"Geller","year":"2003"},{"key":"2026052711492618400_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0197-2456(87)90153-X","article-title":"Issues in designing sequential stopping rules for monitoring side effects in clinical trials","volume":"8","author":"Goldman","year":"1987","journal-title":"Controlled Clinical Trials"},{"key":"2026052711492618400_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1541-0420.2005.00311.x","article-title":"Continuous toxicity monitoring in phase II trials in oncology","volume":"61","author":"Ivanova","year":"2005","journal-title":"Biometrics"},{"key":"2026052711492618400_bib7","doi-asserted-by":"crossref","DOI":"10.1201\/9780367805326","volume-title":"Group Sequential Methods with Applications to Clinical Trials","author":"Jennison","year":"1999"},{"key":"2026052711492618400_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1740774510382799","article-title":"A modified toxicity probability interval method for dose-finding trials","volume":"7","author":"Ji","year":"2010","journal-title":"Clinical Trials"},{"key":"2026052711492618400_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/2168479014525378","article-title":"A Bayesian stopping rule for sequential monitoring of serious adverse events","volume":"48","author":"Kashiwabara","year":"2014","journal-title":"Therapeutic Innovation and Regulatory Science"},{"key":"2026052711492618400_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/07474946.2011.539924","article-title":"A maximized sequential probability ratio test for drug and vaccine safety surveillance","volume":"30","author":"Kulldorff","year":"2011","journal-title":"Sequential Analysis"},{"key":"2026052711492618400_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/biostatistics\/kxz007","article-title":"Time-to-event model-assisted designs for dose-finding trials with delayed toxicity","volume":"21","author":"Lin","year":"2020","journal-title":"Biostatistics (Oxford, England)"},{"key":"2026052711492618400_bib12","first-page":"507","article-title":"Bayesian optimal interval designs for phase I clinical trials","volume":"64","author":"Liu","year":"2015","journal-title":"Journal of the Royal Statistical Society: Series C (Applied Statistics)"},{"key":"2026052711492618400_bib13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/sim.5597","article-title":"The use of group sequential designs with common competing risks tests","volume":"32","author":"Logan","year":"2013","journal-title":"Statistics in Medicine"},{"key":"2026052711492618400_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/17407745241304119","article-title":"Sequential monitoring of time-to-event safety endpoints in clinical trials","volume":"22","author":"Martens","year":"2025","journal-title":"Clinical Trials"},{"key":"2026052711492618400_bib15","article-title":"R software package \u201cstoppingrule\u201d. The comprehensive R archive network","author":"Martens","year":"2025"},{"key":"2026052711492618400_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/17407745231203391","article-title":"Statistical rules for safety monitoring in clinical trials","volume":"21","author":"Martens","year":"2024","journal-title":"Clinical Trials"},{"key":"2026052711492618400_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"2026052711492618400_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"key":"2026052711492618400_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group sequential methods in the design and analysis of clinical trials","volume":"64","author":"Pocock","year":"1977","journal-title":"Biometrika"},{"key":"2026052711492618400_bib20","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"2026052711492618400_bib21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11009-017-9586-z","article-title":"Type I error probability spending for post-market drug and vaccine safety surveillance with Poisson data","volume":"20","author":"Silva","year":"2018","journal-title":"Methodology and Computing in Applied Probability"},{"key":"2026052711492618400_bib22","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1002\/sim.9094","article-title":"Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data","volume":"40","author":"Silva","year":"2021","journal-title":"Statistics in Medicine"},{"key":"2026052711492618400_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2307\/2533377","article-title":"Practical Bayesian guidelines for phase IIB clinical trials","volume":"50","author":"Thall","year":"1994","journal-title":"Biometrics"},{"key":"2026052711492618400_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1214\/aoms\/1177731118","article-title":"Sequential tests of statistical hypotheses","volume":"16","author":"Wald","year":"1945","journal-title":"The Annals of Mathematical Statistics"},{"key":"2026052711492618400_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2307\/2531959","article-title":"Approximately optimal one-parameter boundaries for group sequential trials","volume":"43","author":"Wang","year":"1987","journal-title":"Biometrics"},{"key":"2026052711492618400_bib26","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-0220","article-title":"Keyboard: a novel Bayesian toxicity probability interval design for phase I clinical trials","volume":"23","author":"Yan","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"2026052711492618400_bib27","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-18-0246","article-title":"Time-to-event Bayesian optimal interval design to accelerate phase I trials","volume":"24","author":"Yuan","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"2026052711492618400_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/19466315.2015.1117017","article-title":"Statistical monitoring of safety in clinical trials","volume":"8","author":"Zhu","year":"2016","journal-title":"Statistics in Biopharmaceutical Research"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/2\/ujag097\/68411495\/ujag097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/2\/ujag097\/68411495\/ujag097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:49:39Z","timestamp":1779896979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/doi\/10.1093\/biomtc\/ujag097\/8696197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1093\/biomtc\/ujag097","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,9]]},"article-number":"ujag097"}}